DURAVYU
vorolanib · vorolanib intravitreal insert · EYP-1901 Small Molecule Target: VEGF receptors, PDGF, JAK1, IL-6, VEGF, PDGF receptor, IL-6/JAK1
EyePoint
Most recent annual filing: 2026-03-05
- DURAVYU LUCIA toplinemid-2026DURAVYU LUCIA topline, mid-2026, thesis-defining
- DURAVYU LUGANO toplineAug 2026DURAVYU LUGANO topline, Aug 2026, thesis-defining
- COMO/CAPRI DME Ph3 topline4Q 2027COMO/CAPRI DME Ph3 topline, 4Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
DURAVYU
vorolanib · EYP-1901 Small Molecule Target: VEGF receptors, PDGF, JAK1, IL-6, VEGF, PDGF receptor, IL-6/JAK1
razuprotafib
EYP-2301 Small Molecule Target: TIE-2, VE-PTP
- Undisclosed indication
Technology platforms
Durasert E
Next-generation bioerodible intravitreal drug delivery technology designed to provide sustained release of drug for at least six months without free-floating drug particles; used as the delivery vehicle for vorolanib in DURAVYU for serious retinal diseases including wet AMD and DME.
Biotech Distilled coverage (6)
- 2026-08-17 UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis.
- 2026-08-06 UPDATE: EyePoint (EYPT) - The Last Quarter Before the Verdict 🔒 Paid
- 2026-07-30 UPDATE: EyePoint (EYPT) - The Binary Event Now Has a Month 🔒 Paid
- 2026-07-17 UPDATE: EyePoint (EYPT) — The DOJ Overhang Clears for Pocket Change 🔒 Paid
- 2026-05-07 UPDATE: EyePoint (EYPT) — Q1 2026 Status Check Into the LUGANO Window 🔒 Paid
- 2026-05-01 EyePoint Pharmaceuticals (EYPT) - Scientific Deep Dive for DURAVYU and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.